Stocks Health care CRBP
NASDAQ · Health careCorbus Pharmaceuticals Holdings, Inc. (CRBP)
It posted a net loss of $101.9M. In fiscal 2025 capital spending exceeded operating cash flow by $64.5M. At June 30, 2026 it held $23.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
Key facts about Corbus Pharmaceuticals Holdings, Inc.
- Net worth
- Corbus Pharmaceuticals Holdings, Inc. has a market value (market cap) of $68.3M at the latest share price, and shareholders' equity of $102.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2022 revenue was $0 (-100.0% year on year), with a net loss of $42.3M.
- Cash flow
- In fiscal 2025 operations used $64.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 6, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Corbus Pharmaceuticals Holdings, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Corbus Pharmaceuticals Holdings, Inc. does
Corbus Pharmaceuticals Holdings, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CRBP.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$78.5M | -$5.90 | -$64.5M |
| 2024 | n/a | -$40.2M | -$3.68 | -$41.8M |
| 2023 | n/a | -$44.6M | -$10.31 | -$36.1M |
| 2022 | $0 | -$42.3M | -$10.15 | -$37.6M |
| 2021 | $881.7K | -$45.6M | -$11.15 | -$48.2M |
| 2020 | $3.9M | -$111.3M | -$42.79 | -$100.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Corbus Pharmaceuticals Holdings, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 2, 2026Passive stake changed SCHEDULE 13G/A
- October 29, 2026Passive stake changed SCHEDULE 13G/A
- October 15, 2026
- September 30, 2026Passive stake (5% or more) SCHEDULE 13G
- September 14, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026
- August 6, 2026
- July 27, 2026Passive stake (5% or more) SCHEDULE 13G
- July 6, 2026
Insider trades
What the people running Corbus Pharmaceuticals Holdings, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $1.8M worth of shares in the last 90 days and bought none on the open market. 1% of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 29, 2026 | Cormorant Asset Management, LPFormer 10% Owner | Soldindirect | 425,000 | $1.7M |
| September 14, 2026 | Ben YongDirector | Soldpre-planned (10b5-1) | 2,000 | $15.7K |
| August 16, 2026 | Nicacio Leonardo VianaChief Medical Officer | Received as pay | 58,333 | - |
| August 11, 2026 | Saxena Nishant CChief Business Officer | Bought | 2,600 | $25K |
| August 7, 2026 | Moran Sean F.Chief Financial Officer | Soldpre-planned (10b5-1) | 12,000 | $121K |
| August 7, 2026 | Cohen YuvalChief Executive Officer, Director | Soldpre-planned (10b5-1) | 17,000 | $171.4K |
| June 10, 2026 | Altmeyer AnneDirector | Soldpre-planned (10b5-1) | 2,412 | $19.1K |
| June 10, 2026 | Jenkins John KennethDirector | Soldpre-planned (10b5-1) | 4,800 | $38K |
Who owns CRBP
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| RA Capital Management, L.P.13G, passive with 3 related filers | 9.9% | September 30, 2026 |
| Cormorant Asset Management, LP13G, passive with 1 related filers | 7.76% | November 2, 2026 |
| Aberdeen Group plc13G, passive with 1 related filers | 7.53% | January 16, 2026 |
| OrbiMed Capital LLC13G, passive with 1 related filers | 5.9% | February 14, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 107 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Cormorant Asset Management, LP | 2,344,971 | 0 |
| Orbimed Advisors LLC | 1,737,287 | 0 |
| BlackRock, Inc. | 1,331,135 | +1,059,499 |
| Aberdeen Group plc | 1,321,750 | 0 |
| Vanguard Capital Management LLC | 760,940 | +26,834 |
| Jones Hill Capital LP | 653,572 | new |
| Prosight Management, LP | 650,000 | -47,108 |
| Stonepine Capital Management, LLC | 425,000 | +41,538 |
| Geode Capital Management, LLC | 423,374 | +236,345 |
| ADAR1 Capital Management, LLC | 421,787 | +90,006 |
| Diadema Partners LP | 301,264 | -138,693 |
| Susquehanna International Group, Llp | 293,203 | -40,212 |
| State Street Corp | 254,672 | +185,800 |
| Dimensional Fund Advisors LP | 190,214 | +53,612 |
| Exome Asset Management LLC | 184,914 | -49,222 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 151,640 | -8,822 |
| Jane Street Group, LLC | 139,133 | +65,940 |
| Northern Trust Corp | 124,906 | +83,402 |
| Vanguard Fiduciary Trust Co | 112,397 | +16,156 |
| Vanguard Portfolio Management LLC | 111,302 | +86,937 |
Insiders
13 insiders reported holding 2,490,902 shares in total, about $8.8M at the last price.
| Holder | Shares |
|---|---|
| Cormorant Asset Management, LPFormer 10% Owner | 1,919,9711,919,971 held indirectly |
| Cohen YuvalChief Executive Officer, Director | 157,316 |
| Smethurst DominicChief Medical Officer | 89,790 |
| Moran Sean F.Chief Financial Officer | 84,694 |
| Saxena Nishant CChief Business Officer | 77,900 |
| Nicacio Leonardo VianaChief Medical Officer | 58,333 |
| Hodgson IanChief Operating Officer | 51,080 |
| Kung WinstonDirector | 12,140 |
| Jacques Rachelle SuzanneDirector | 11,383 |
| Ben YongDirector | 9,383 |
Questions about CRBP
What does Corbus Pharmaceuticals Holdings, Inc. do?
Corbus Pharmaceuticals Holdings, Inc. is a company in the Health care sector, listed on NASDAQ as CRBP. Its shares trade on NASDAQ under the ticker CRBP.
What is Corbus Pharmaceuticals Holdings, Inc.'s net worth?
Corbus Pharmaceuticals Holdings, Inc. has a market value (market cap) of $68.3M at the latest share price, and shareholders' equity of $102.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Corbus Pharmaceuticals Holdings, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $101.9M.
When did Corbus Pharmaceuticals Holdings, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake changed from November 2, 2026.
When is Corbus Pharmaceuticals Holdings, Inc.'s next earnings report?
Corbus Pharmaceuticals Holdings, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare CRBP with
Follow CRBP
Get an email when Corbus Pharmaceuticals Holdings, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Corbus Pharmaceuticals Holdings, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.